Biotech News

Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study

Precision BioSciences (DTIL)Precision BioSciencesClinical readout

- First patient completed observation period following PBGENE-DMD treatment with no reported safety concerns - - Independent Data Safety Monitoring Board endorses proceeding with dosing additional patients - DURHAM, N.C. --(BUSINESS WIRE)--Nov. 5, 2026-- Precision BioSciences, Inc.

Related news

Precision BioSciences

ARCUS Gene Editing Platform Precision BioSciences develops in vivo gene-editing therapies using ARCUS nucleases. The compact enzymes are designed for several editing modes, including elimination of viral DNA, excision of defective genomic regions and targeted insertion of functional genetic material. PBGENE-HBV PBGENE-HBV is a wholly...

Recent company news

Stock data

Close
6.91 USD
Market cap
163.07M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States